OrthoSera launches BoneAlbumin for musculoskeletal indications
After a series of clinical studies showed positive effects of the patented albumin coating technology, there was a strong demand among physicians to use this graft.
OrthoSera (formerly Lacerta Technologies), an orthobiologics company developing serum-based solutions for musculoskeletal indications has reached a major milestone by putting their first product on the market. BoneAlbumin is a serum albumin enhanced bone substitute made of fully human materials of donated bone and blood. After a series of clinical studies showed positive effects of the patented albumin coating technology, there was a strong demand among physicians to use this graft. Classification of BoneAlbumin as a 'human tissue product' opened the possibility for distribution through regional tissue banks.
The field of bone grafts is among the most promising markets in the orthopedic industry, generating more than 2 bn USD revenues globally and capturing an ever growing segment of the total orthobiologics market. The majority of bone substitutes are used in orthopedics and spine surgery while the dental field offers an additional opportunity with uniform dosing and self-paying customers. In order to capture this market opportunity OrthoSera launched a dental subsidiary with independent management and financing.
The Hungarian institutional investor Széchenyi Capital Investment Fund invested in OrthoSera Dental in exchange for a minority stake in the company. József Török, BizDev and Startup Director at the Fund comments: “Hungary is the leading global destination for dental tourism. Our investment enables the successful establishment of a fully human alternative to existing bone graft solutions in this segment further adding to the competitive advantage of regional dentists and implantologists.”
"Upon market entry with BoneAlbumin as our first commercial product we could convince a strong financing partner to join forces in setting up a fully-funded new entity. This is reflecting our transition to a commercial-stage company with additional exciting projects in the development pipeline. We felt that this is the perfect time to transform into OrthoSera," stresses Dr Zsombor Lacza, CEO of OrthoSera GmbH. "We expect to reach more significant milestones in the near future further underscoring our ambition to become a leading player in orthobiologics."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance